1S70 Stock Chart & Stats
€8.05
€0.15(2.33%)
At close: 4:00 PM EDT
€8.05
€0.15(2.33%)
Day’s Range― - ―
52-Week Range€4.68 - €9.60
Previous CloseN/A
Volume11.00
Average Volume (3M)37.00
Market Cap
€188.72M
Enterprise Value€227.40M
Total Cash (Recent Filing)€147.61M
Total Debt (Recent Filing)€63.85M
Price to Earnings (P/E)―
Beta2.01
Next Earnings
Nov 05, 2026EPS Estimate
-0.89Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.93
Shares Outstanding30,255,352
10 Day Avg. Volume26
30 Day Avg. Volume37
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)-1.48
Price to Sales (P/S)66.95
P/FCF Ratio-2.36
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€29.01Price Target Upside260.32% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-2.64
Revenue Forecast (FY)€372.79K
Bulls Say, Bears Say
Bulls Say
Durable Clinical BenefitSustained symptom improvement after retreatment supports the potential durability of Descartes-08’s clinical benefit rather than a transient response. This may strengthen the program’s treatment profile, support advancement toward Phase 3, and improve its future commercialization prospects if larger studies confirm the results.
Favorable Safety ProfileThe reported safety and tolerability profile, including no new safety concerns, could support adoption of an outpatient, chemotherapy-free treatment approach. A manageable administration profile may also reduce practical barriers for physicians and patients as the lead program progresses through development.
Non-permanent Cell EngineeringTransient mRNA engineering differentiates Cartesian’s platform from permanently modified cell therapies and is designed to deliver targeted receptor activity without lasting genetic alteration. This approach may support repeat dosing and broaden applicability across autoimmune diseases if clinical efficacy and safety continue to validate the platform.
Bears Say
Severe Revenue ContractionThe steep decline in revenue underscores that Cartesian remains pre-commercial and lacks a stable operating revenue base. Until a product or durable collaboration revenue stream emerges, the company’s financial outlook remains highly dependent on clinical execution and continued access to external funding.
Persistent Operating LossesDeep and sustained losses indicate that current operations are not economically self-sustaining and that future development spending is not being funded by commercial earnings. Continued losses could constrain strategic flexibility and increase the financing required before any investigational therapy can generate product revenue.
Ongoing Cash BurnSustained negative operating and free cash flow creates a recurring need to fund research, trials, and corporate activities through external financing. Because cash burn has not materially improved, the company remains exposed to dilution or financing constraints during the path toward potential commercialization.
Cartesian Therapeutics News
1S70 FAQ
What was Cartesian Therapeutics’s price range in the past 12 months?
Cartesian Therapeutics lowest stock price was €4.68 and its highest was €9.60 in the past 12 months.
What is Cartesian Therapeutics’s market cap?
Cartesian Therapeutics’s market cap is €188.72M.
When is Cartesian Therapeutics’s upcoming earnings report date?
Cartesian Therapeutics’s upcoming earnings report date is Nov 05, 2026 which is in 22 days.
How were Cartesian Therapeutics’s earnings last quarter?
Cartesian Therapeutics released its earnings results on Aug 06, 2026. The company reported €0.406 earnings per share for the quarter, beating the consensus estimate of -€0.775 by €1.18.
Is Cartesian Therapeutics overvalued?
According to Wall Street analysts Cartesian Therapeutics’s price is currently Undervalued.
Does Cartesian Therapeutics pay dividends?
Cartesian Therapeutics does not currently pay dividends.
What is Cartesian Therapeutics’s EPS estimate?
Cartesian Therapeutics’s EPS estimate is -0.89.
How many shares outstanding does Cartesian Therapeutics have?
Cartesian Therapeutics has 30,255,352 shares outstanding.
What happened to Cartesian Therapeutics’s price movement after its last earnings report?
Cartesian Therapeutics reported an EPS of €0.406 in its last earnings report, beating expectations of -€0.775. Following the earnings report the stock price went up 2.878%.
Which hedge fund is a major shareholder of Cartesian Therapeutics?
Currently, no hedge funds are holding shares in DE:1S70
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cartesian Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€29.01 (260.32% Upside)
€29.01 (260.32% Upside)
Blogger Sentiment
Bullish
DE:1S70 Sentiment 100%
Sector Average 67%
Sector Average 67%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-25.00%
12-Months-Change
Fundamentals
Return on Equity
141.41%
Trailing 12-Months
Asset Growth
-18.07%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Cartesian Therapeutics
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
1S70 Stock 12 Month Forecast
Average Price Target
€29.01
▲(260.32% Upside)